Zobrazeno 1 - 10 of 47 pro vyhledávání: '"Peter T.C. Ho"'
1
Akademický článek
A Double‐Blind, Phase I, Single Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of BOS161721 in Healthy Subjects
Autor: Azra Hussaini, Rajat Mukherjee, Dina M. Berdieva, Christen Glogowski, Richard Mountfield, Peter T.C. Ho
Publikováno v: Clinical and Translational Science, Vol 13, Iss 2, Pp 337-344 (2020)
The purpose of this study was to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of BOS161721, a humanized immunoglobulin G1 triple mutation (M252Y/S254T/T256E) monoclonal antibody that inhibits interleukin‐2
Externí odkaz: https://doaj.org/article/b36ecae080e7425db420993303572fc3
Zobrazit plný text záznamu
3
A Double‐Blind, Phase I, Single Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of BOS161721 in Healthy Subjects
Autor: Richard Mountfield, Dina M. Berdieva, Rajat Mukherjee, Peter T.C. Ho, Azra Hussaini, Christen Glogowski
Publikováno v: Clinical and Translational Science, Vol 13, Iss 2, Pp 337-344 (2020)
Clinical and Translational Science
The purpose of this study was to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of BOS161721, a humanized immunoglobulin G1 triple mutation (M252Y/S254T/T256E) monoclonal antibody that inhibits interleukin-21
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dc500739dd2b26a694dc69b112167e87
https://doi.org/10.1111/cts.12715
Zobrazit plný text záznamu
4
Selective Killing of SMARCA2- and SMARCA4-deficient Small Cell Carcinoma of the Ovary, Hypercalcemic Type Cells by Inhibition of EZH2: In Vitro and In Vivo Preclinical Models
Autor: Igor Feldman, Elayne Chan-Penebre, Alexandra R. Grassian, Kelli A. Armstrong, Kristy Kuplast-Barr, John Campbell, Sarah K. Knutson, Heike Keilhack, Maria Roche, Peter T.C. Ho, Scott Ribich, J. Joshua Smith, Robert A. Copeland, Richard Chesworth, Allison Drew
Publikováno v: Molecular Cancer Therapeutics. 16:850-860
The SWI/SNF complex is a major regulator of gene expression and is increasingly thought to play an important role in human cancer, as evidenced by the high frequency of subunit mutations across virtually all cancer types. We previously reported that
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::747f40bb502acb9ed4d112bf0f390043
https://doi.org/10.1158/1535-7163.mct-16-0678
Zobrazit plný text záznamu
5
24 Phase 1 study in healthy volunteers to assess PK, PD safety & tolerability of BOS161721, an extended half-life anti-IL21 monoclonal antibody
Autor: Peter T.C. Ho, Xavier Valencia, Christen Glogowski, Richard Mountfield, Azra Hussaini
Publikováno v: Abstracts.
Background Interleukin-21 (IL-21) is a pleiotropic cytokine. Both IL-21 and the IL-21 receptor (IL-21R) have been shown to be upregulated in systemic lupus erythematosus (SLE). BOS161721, a humanized monoclonal immunoglobulin (IgG1) that binds to and
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8ae7a3f2dc719ee8021cce9470099c7e
https://doi.org/10.1136/lupus-2019-lsm.24
Zobrazit plný text záznamu
8
Abstract 2199: BOS172738: A novel highly potent and selective RET kinase inhibitor in Phase 1 clinical development
Autor: Keith M. Wilcoxen, Mitchell Keegan, Peter T.C. Ho
Publikováno v: Cancer Research. 79:2199-2199
Background: RET gene alterations including point mutations and gene fusions have been detected in multiple cancers, including colorectal cancer, NSCLC and various thyroid cancers. RET fusion events involve the kinesin family member 5B (KIF5B-RET), as
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4265f21ea7bb679ef4be95455e13935c
https://doi.org/10.1158/1538-7445.am2019-2199
Zobrazit plný text záznamu
9
A phase I study of BOS172738 in patients with advanced solid tumors with RET gene alterations including non-small cell lung cancer and medullary thyroid cancer
Autor: Christiane Jungels, Patrick Schöffski, Philippe Aftimos, Christophe Massard, Antoine Italiano, Peter T.C. Ho, Karen Andreas, Mitchell Keegan
Publikováno v: Journal of Clinical Oncology. 37:TPS3162-TPS3162
TPS3162 Background: RET gene alterations (mutations and fusions) leading to constitutive kinase activity have been identified in various tumor types including non-small cell lung cancer (NSCLC), medullary thyroid (MTC), colon, breast and ovarian canc
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a81e134ba3ef710eb15e85c357c09d14
https://doi.org/10.1200/jco.2019.37.15_suppl.tps3162
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje